An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib

Lung Cancer

Volumn 82, Issue 1, 2013, Pages 136-142

  Hilton, J F ^a   Tu, D ^a   Seymour, L ^a   Shepherd, F A ^b   Bradbury, P A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Bioavailability; Drug drug interactions; Erlotinib; H2 receptor antagonist; Pharmacokinetics; Proton pump inhibitors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH ACID;

BIOAVAILABILITY; DRUG-DRUG INTERACTIONS; ERLOTINIB; H2-RECEPTOR ANTAGONIST; PHARMACOKINETICS; PROTON PUMP INHIBITORS;

ANTI-ULCER AGENTS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; OMEPRAZOLE; PROTON PUMP INHIBITORS; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RANITIDINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; STOMACH ULCER; TREATMENT OUTCOME;

EID: 84884414191     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.06.008     Document Type: Article

References (14)

1. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
2. Moore M.J., Goldstein D., Hamm J., Figer A., Hecht J.R., Gallinger S., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
3. Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006, 12:2166-2171.
4. Canada R. Prescribing information Tarceva (erlotinib). , 2011. http://www.gene.com/gene/products/information/pdf/tarceva-prescribing.pdf.
5. Ter Heine R., Fanggiday J.C., Lankheet N.A., Beijnen J.H., Van Der Westerlaken M.M., Staaks G.H., et al. Erlotinib and pantoprazole: a relevant interaction or not?. Br J Clin Pharmacol 2010, 70:908-911.
6. Fisher R.S., Sher D.J., Donahue D., Knight L.C., Maurer A., Urbain J.L., et al. Regional differences in gastric acidity and antacid distribution: is a single pH electrode sufficient?. Am J Gastroenterol 1997, 92:263-270.
7. Duong S., Leung M. Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents. J Oncol Pharm Pract 2011, 17:448-452.
8. Ding K., Pater J., Whitehead M., Seymour L., Shepherd F.A. Validation of treatment induced specific adverse effect as a predictor of treatment benefit: a case study of NCIC CTG BR21. Contemp Clin Trials 2008, 29:527-536.
9. Squibb B.-M. Prescribing Information Sprycel(R) (dasatinib). , 2011. http://www.bmscanada.ca/static/products/en/pm_pdf/SPRYCEL_PM_E_26%20July%202011_APP_CLN_DIST.pdf.
10. Yin O.Q., Gallagher N., Fischer D., Demirhan E., Zhou W., Golor G., et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010, 50:960-967.
11. Hidalgo M., Siu L.L., Nemunaitis J., Rizzo J., Hammond L.A., Takimoto C., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001, 19:3267-3279.
12. Gosselin A., Luo R., Lohoues H., Toy E., Lewis B., Crawley J., et al. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease. Value Health 2009, 12:34-39.
13. Eechoute K., Fransson M.N., Reyners A.K., de Jong F.A., Sparreboom A., van der Graaf W.T., et al. A long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patients. Clin Cancer Res 2012, 18:5780-5787.
14. Herzig S.J., Howell M.D., Ngo L.H., Marcantonio E.R. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 2009, 301:2120-2128.